At the end of their cycle, hematocrit amounts had greater by three%-level compared with baseline. The rise was not related to lengthier use or greater AAS dose. A cause of this might be that, outside of a particular standard of androgenic action, no even further raise of hematocrit happens: a ‘ceiling result’. Notably, While only five% of subje